Mriglobal is a 501(c)(3) organization based in Kansas City, Missouri, registered in 1946, with $117,952,952 in FY2023 revenue. CharityIndex grades it A, and it directs about 80% of spending to programs.
Revenue (FY2023)
$118.0M
▼ 1.4% vs prior year
Science & Tech median: $288K
Expenses (FY2023)
$115.3M
Net assets
$110.8M
Employees
493
Measures how much of every dollar spent actually reaches programs, plus what it costs to raise $100 of donations. The worse of the two measures sets the letter (85%+ to programs is an A; under $15 to raise $100 is an A), averaged over the three most recent filings. For Mriglobal: 80% to programs · $0 to raise $100 earns a A on this criterion. See the exact thresholds →
Measures whether the organization is built to last: how many months its reserves would cover expenses (3+ months earns an A-range score, but hoarding 5+ years of budget is capped) and whether it runs a surplus or a deficit. For Mriglobal: 12 mo reserves · +2% margin earns a A on this criterion. See the exact thresholds →
Checks how the organization is run, from its own Form 990: an independent board majority, a board of five or more, conflict-of-interest, whistleblower and document-retention policies, and independently audited financials. The share of disclosed checks that pass sets the letter. For Mriglobal: 6 of 6 checks met earns a A+ on this criterion. See the exact thresholds →
Counts five disclosure signals: a recent filing, a mission statement, program descriptions, a listed website, and the full expense breakdown. More disclosure, better letter. For Mriglobal: 5 of 5 disclosure signals earns a A+ on this criterion. See the exact thresholds →
Show this grade on your website
A live seal — it updates automatically when the grade changes and links donors to this verified profile.
Advance scientific and engineering research to support our government and commercial customers.
Integrated defense solutions - mriglobal guards human health and safety by defending against chemical, biological, and explosive threats. with decades of chemical warfare agent detection, evaluation, and assessment, our unique expertise and history combines scientific and engineering experts with state-of-the-art laboratory facilities to advance programs across the united states government and private sectors. this includes the design, building, testing, and evaluation of advanced products and technologies such as miniature devices capable of detecting toxic materials and chemical agents, field-deployable laboratories, and medical response systems that improve national defense and global health.
Integrated pharmaceutical solutions - mriglobal bridges the gap between drug discovery and commercialization. we provide the necessary services including development, manufacturing, testing, and clinical trial material management support for drug substances, drug products, intermediates, and impurities, including reference standard materials. our team works in the appropriate regulatory framework, such as glp, gmp, and in accordance with ich guidelines to ensure strict compliance to quality and regulatory requirements. this work helps support informed public health decisions, and guiding investigational new drugs through development, clinical trials, and regulatory approvals.
Translational development - mriglobal scientists have unsurpassed technical expertise in defending against chemical and biological threats. this includes support for the discovery and development, and assessing the safety and efficacy, of regulatory compliant pre-clinical and non-clinical medical countermeasures to prevent or mitigate the adverse health effects of global health risks such as bioterrorism, infectious diseases, and chemical threat agents.
Revenue grew from $88.9M (FY2013) to $118.0M (FY2023) across 11 reported years.
Financial snapshot
Operating margin
2.3%
Revenue exceeded expenses in the latest fiscal year.
Total assets
$147.8M
Total liabilities
$37.0M
Net assets
$110.8M
Salaries & benefits
$57.7M
50% of expenses
Board members
14
13 independent
| Fiscal year | Revenue | Expenses | Net assets | Total assets | Form |
|---|---|---|---|---|---|
| 2023 | $117,952,952▼1.4% | $115,298,058▲2.2% | $110,802,984▲7.8% | $147,828,702▼0.5% | 990 |
| 2022 | $119,632,626▼7.0% | $112,859,972▼6.9% | $102,782,665▲16.6% | $148,628,423▲7.9% | 990 |
| 2021 | $128,594,894▲10.8% | $121,200,941▲12.6% | $88,157,913▲26.7% | $137,683,275▲3.2% | 990 |
| 2020 | $116,109,484▲13.1% | $107,631,775▲13.2% | $69,598,528▲36.5% | $133,438,499▲14.1% | 990 |
| 2019 | $102,654,783▼5.8% | $95,114,232▼8.2% | $50,992,420▲22.0% | $116,923,133▲13.6% | 990 |
| 2018 | $108,959,622▼0.6% | $103,621,879▼1.5% | $41,812,208▲7.7% | $102,952,763▲10.3% | 990 |
| 2017 | $109,624,647▲43.4% | $105,149,771▲32.3% | $38,829,281▲44.1% | $93,326,926▲14.1% | 990 |
| 2016 | $76,452,611▼9.1% | $79,505,115▼7.2% | $26,940,513▲17.2% | $81,760,619▼1.1% | 990 |
| 2015 | $84,133,544▼7.2% | $85,667,766▼9.9% | $22,984,061▼0.7% | $82,646,792▲4.1% | 990 |
| 2014 | $90,685,943▲2.0% | $95,066,967▲3.0% | $23,136,639▼36.4% | $79,355,553▼4.5% | 990 |
| 2013 | $88,925,929 | $92,265,464▼30.7% | $36,367,382▼1.4% | $83,108,046▼10.0% | 990 |
| 2011 | — | $133,110,186▼0.2% | $36,899,898▼13.9% | $92,339,118▼2.7% | 990 |
| 2010 | — | $133,442,572▲17.2% | $42,862,056▲11.2% | $94,930,546▲4.9% | 990 |
| 2009 | — | $113,818,359 | $38,533,704 | $90,489,546 | 990 |
Original Form 990 PDFs (the Form column) are served by ProPublica Nonprofit Explorer, as filed with the IRS. Create a free account to download the CSV report.
Highest-paid: Ian M Colrain Phd — $651,041 (0.56% of total expenses)
| Name | Title | Hours/week | Compensation |
|---|---|---|---|
| Ian M Colrain Phd | President and Ceo | 40 | $651,041 |
| Reachel A Beichley | Vp/general Counsel/corp. Sec. - Outgoing | 0 | $645,171 |
| Martin J Nevshemal | Cfo and Treasurer | 40 | $469,983 |
| Richard T Fleener | Sr Vp-lab Ops & Gov Affairs | 40 | $412,881 |
| Amy M Bog Phd | Chief Innovation Officer | 40 | $332,673 |
| Luke J Mcglynn | Chief People Officer | 40 | $292,068 |
| Richard A Winegar | Distinguished Research Fellow | 40 | $282,102 |
| Dominie Garcia Phd | Vp-commercial Business Development | 40 | $258,100 |
| Richard S Masino | Senior Sales Director | 40 | $257,539 |
| Aaron M Heiss | Senior Sales Director | 40 | $256,629 |
| Joseph A Bogan Phd | Vp-chief Research Fellow | 40 | $249,792 |
| Gene G Olinger | Distinguished Research Fellow | 40 | $249,042 |
| Kristine K Werking | Senior Director | 40 | $243,763 |
| James E Sistrunk | Senior Sales Director | 40 | $232,662 |
| Christopher W Hollars | Principal Advisor | 40 | $227,759 |
| Dean E Gray | Chief Operating Officer - Outgoing | 0 | $222,009 |
| Jerem G Swenddal | Vp-business Ops & Strategy | 40 | $212,991 |
| Jonathan M White | Senior Director | 40 | $206,764 |
| Carol F Blevins | Assistant Director | 40 | $193,214 |
| Scott M King | Vp-business Operations - Outgoing | 0 | $188,875 |
| Contractor | Services | Paid |
|---|---|---|
| Draper Laboratory | Research & Development | $4,350,854 |
| Domenix Corporation | Research & Development | $2,464,268 |
| Forgefx | Research & Development | $1,942,150 |
| Ohio State University | Research & Development | $1,922,403 |
| Conductive Technologies | Research & Development | $1,784,598 |
19 grants to Mriglobal totaling $3.1M, reported by foundations on their Schedule I filings — showing the 15 most recent.
| Grantmaker | Purpose | Year | Amount |
|---|---|---|---|
| Greater Kansas City Community Foundation | Health, medicine & science | 2024 | $50,000 |
| Yale University | Subaward - sponsored research | 2023 | $40,632 |
| Johns Hopkins University | Sub-award | 2023 | $11,711 |
| Johns Hopkins University | Sub-award | 2022 | $600,890 |
| Yale University | Subaward - sponsored research | 2022 | $13,302 |
| Johns Hopkins University | Sub-award | 2021 | $432,386 |
| Electric Power Research Institute Inc | Contribution | 2021 | $50,000 |
| Johns Hopkins University | Sub-award | 2020 | $1,052,174 |
| J Craig Venter Institute Inc | Research subgrant | 2020 | $117,251 |
| Foundation For Innovative New Diagnostics Find | Lab testing & system assistance | 2020 | $25,224 |
| Greater Kansas City Community Foundation | Science & technology | 2019 | $304,420 |
| Johns Hopkins University | Sub-award | 2019 | $102,161 |
| J Craig Venter Institute Inc | Research subgrant | 2019 | $26,024 |
| Greater Kansas City Community Foundation | Science & technology | 2018 | $15,334 |
| Johns Hopkins University | Sub-award | 2017 | $87,995 |
1 grant totaling $25K in FY2023. All grants made by Mriglobal →
| Recipient | Purpose | Amount |
|---|---|---|
| Union Station Kansas City Inc | Foster scientific education | $25,000 |
Explore more
Data for Mriglobal (EIN 44-0545878) comes from the IRS Business Master File and e-filed Form 990 returns, via CharityIndex. Figures reflect what the organization reported to the IRS for each fiscal year.